Sucampo Pharma, Ltd Initiates Phase 1 Study of SPL-017 for Peripheral Arterial Disease

Published: Dec 18, 2008

BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharma, Ltd., of Japan, a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced that it has initiated dosing in a first-in-human clinical safety study of a proprietary prostone, SPL-017, as a potential treatment for peripheral arterial disease (PAD).

Back to news